

FIGURE 2

High-resolution G-banding of chromosome 11 and fluorescence in situ hybridization (FISH) in patient 2 and G-banding of chromosome 11 in patient 3. A, Patient 2 had deletion of chromosome 11p13-p14.2 in one allele. B, FISH using P1-derived artificial chromosome clones (1083G3 for *PAX6*, 65P5 for *D11S2163*, 685F3 for *PER*, and 104M13 for *WT1*) as probes was performed for patient 2, as previously reported.⁶ Each FISH signal for *PAX6*, *D11S2163*, *PER*, and *WT1* was observed in only one chromosome 11 homolog, indicating heterozygous deletion of the WAGR region of 11p. C, Patient 3 had deletion of chromosome 11p13-p14 in one allele.

histology. The possibility of reflux nephropathy, however, could not be ruled out in patient 2. The perihilar variant with glomerular hypertrophy is particularly common in the secondary FSGS such as reduced renal mass–induced FSGS.⁸ However, all 3 patients exhibited FSGS (not otherwise specified) without glomerular hypertrophy, suggesting that surgical renal ablation (patient 1) and reflux nephropathy (patient 2) may not have been the main cause of FSGS in these 2 patients. These findings suggest that the complete deletion of one *WT1* allele might have a pathogenetic role in the development of nephropathy.

The spectrum of glomerular diseases associated with *WT1* mutations has been reviewed.⁹ *WT1* mutations can cause syndromic and nonsyndromic glomerular disease. The syndromic forms include DDS (early-onset nephrotic syndrome with diffuse mesangial sclerosis [DMS]); 46,XY disorders of sex development and Wilms' tumor; and Frasier syndrome (disorders of sex development, FSGS, and gonadoblastoma), which is caused by a mutation in the intron 9 splice site of *WT1* leading to the loss of the +KTS isoform of the protein. Mutations associated with both syndromic and nonsyndromic glomerular

disease tend to cluster in exons 8 and 9 of *WT1*, which encode zinc fingers 2 and 3.^{9,10} Orloff et al¹¹ reported that single-nucleotide polymorphisms in *WT1* may modulate the development of FSGS by altering *WT1* function. The current study suggests that complete deletion of one *WT1* allele may also induce the development of nephropathy.

Reduced expression levels of *Wt1*-induced glomerulopathies (crescentic glomerulonephritis or DMS) depending on gene dosage derived by combining *Wt1*-knockout mice and an inducible *Wt1* yeast artificial chromosome transgenic mouse model.¹² Eleven percent of mice heterozygous for the *Wt1* mutation showed severe proteinuria and DMS with tubular cysts, protein casts, and severe interstitial inflammation, although nephrogenesis was not delayed.¹² These findings indicate that the expression level of *WT1* plays an important role, not only during nephrogenesis but also in the homeostasis of normal kidney function. These findings also support our conclusion that complete deletion of one *WT1* allele in atypical WAGR syndrome could induce glomerulopathy without delayed nephrogenesis, although the reason for the discrepancy in histologic findings between man (FSGS) and mouse (DMS) is unclear.

CONCLUSIONS

Besides dominant-negative missense mutations in the eighth or ninth exon of *WT1* and mutations at the donor splice site of intron 9, complete deletion of one *WT1* allele may induce the development of FSGS. The findings in this study also suggest that haploinsufficiency of *WT1* could be responsible for the development of FSGS.

REFERENCES

- Miller RW, Fraumeni JF Jr, Manning MD. Association of Wilms' tumor with aniridia, hemihypertrophy and other congenital malformations. *N Engl J Med*. 1964;270:922-927
- Little MH, Williamson KA, Mannens M, et al. Evidence that *WT1* mutations in Denys-

- Drash syndrome patients may act in a dominant-negative fashion. *Hum Mol Genet.* 1993;2(3):259–264
3. Huff V. Genotype/phenotype correlations in Wilms' tumor. *Med Pediatr Oncol.* 1996;27(5):408–414
 4. Breslow NE, Takashima JR, Ritchey ML, Strong LC, Green DM. Renal failure in the Denys-Drash and Wilms' tumor-aniridia syndromes. *Cancer Res.* 2000;60(15):4030–4032
 5. Kawase E, Tanaka K, Honna T, Azuma N. A case of atypical WAGR syndrome with anterior segment anomaly and microphthalmos. *Arch Ophthalmol.* 2001;119(12):1855–1856
 6. Muto R, Yamamori S, Ohashi H, Osawa M. Prediction by FISH analysis of the occurrence of Wilms tumor in aniridia patients. *Am J Med Genet.* 2002;108(4):285–289
 7. Lee VW, Harris DC. Adriamycin nephropathy: a model of focal segmental glomerulosclerosis. *Nephrology (Carlton).* 2011;16(1):30–38
 8. D'Agati VD. The spectrum of focal segmental glomerulosclerosis: new insights. *Curr Opin Nephrol Hypertens.* 2008;17(3):271–281
 9. Niaudet P, Gubler MC. WT1 and glomerular diseases. *Pediatr Nephrol.* 2006;21(11):1653–1660
 10. Mucha B, Ozaltin F, Hinkes BG, et al; Members of the APN Study Group. Mutations in the Wilms' tumor 1 gene cause isolated steroid resistant nephrotic syndrome and occur in exons 8 and 9. *Pediatr Res.* 2006;59(2):325–331
 11. Orloff MS, Iyengar SK, Winkler CA, et al. Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. *Physiol Genomics.* 2005;21(2):212–221
 12. Guo JK, Menke AL, Gubler MC, et al. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and mesangial sclerosis. *Hum Mol Genet.* 2002;11(6):651–659

ORIGINAL ARTICLE

Subtelomeric deletions of 1q43q44 and severe brain impairment associated with delayed myelination

Keiko Shimojima¹, Nobuhiko Okamoto², Yume Suzuki³, Mari Saito³, Masato Mori³, Tatanori Yamagata³, Mariko Y Momoi³, Hideji Hattori⁴, Yoshiyuki Okano⁴, Ken Hisata⁵, Akihisa Okumura⁵ and Toshiyuki Yamamoto¹

Subtelomeric deletions of 1q44 cause mental retardation, developmental delay and brain anomalies, including abnormalities of the corpus callosum (ACC) and microcephaly in most patients. We report the cases of six patients with 1q44 deletions; two patients with interstitial deletions of 1q44; and four patients with terminal deletions of 1q. One of the patients showed an unbalanced translocation between chromosome 5. All the deletion regions overlapped with previously reported critical regions for ACC, microcephaly and seizures, indicating the recurrent nature of the core phenotypic features of 1q44 deletions. The four patients with terminal deletions of 1q exhibited severe volume loss in the brain as compared with patients who harbored interstitial deletions of 1q44. This indicated that telomeric regions have a role in severe volume loss of the brain. In addition, two patients with terminal deletions of 1q43, beyond the critical region for 1q44 deletion syndrome exhibited delayed myelination. As the deletion regions identified in these patients extended toward centromere, we conclude that the genes responsible for delayed myelination may be located in the neighboring region of 1q43.

Journal of Human Genetics advance online publication, 21 June 2012; doi:10.1038/jhg.2012.77

Keywords: 1q44 deletion; abnormalities of the corpus callosum; *AKT3*; delayed myelination; microcephaly; subtelomeric deletion; *ZNF238*

INTRODUCTION

Submicroscopic subtelomeric chromosomal deletions have been found in 7.4% of children with moderate to severe mental retardation.¹ Some subtelomeric deletion syndromes are clinically recognizable and identified by characteristic features, whereas some others cannot be identified by such means. The recent development of molecular karyotyping using chromosomal microarray testing has revealed clear genotype–phenotype correlations and identified the critical chromosomal regions of the characteristic features of subtelomeric deletions. The most striking example is the Miller-Diecker syndrome, which has shown clear genotype–phenotype correlations.² Miller-Diecker syndrome is caused by the subtelomeric deletion of 17p, and is well recognized and characterized by lissencephaly and distinctive facial features,³ which result from the involvement of the platelet-activating factor acetylhydrolase 1b regulatory subunit 1 gene (*PAFAH1B1*) and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase-activation protein epsilon polypeptide gene (*YWHAE*), respectively; both these genes are located on 17p13.³

Several studies have investigated the critical region for 1q44 subtelomeric deletion syndrome and found that the core phenotypic

features of 1q44 subtelomeric deletion syndrome are microcephaly, abnormalities of the corpus callosum (ACC) and seizures.^{4–16} Recently, Ballif *et al.*¹⁷ analyzed patients with microdeletions of 1q44 and proposed certain genes that may be responsible for individual features.

We report the cases of six newly identified patients with 1q44 deletions; two with interstitial deletion of 1q44; and four with terminal deletion of 1q. As the patients with terminal deletion of 1q44 exhibited more severe phenotypes compared with the patients with interstitial deletion, the phenotypic differences would be derived from additionally deleted region of 1q43q44.

MATERIALS AND METHODS

Subjects

Six Japanese patients were diagnosed as having chromosomal deletions in the region of 1q43q44 in our ongoing study to analyze genomic copy number aberrations. This study was approved by the ethical committee of our institution. After obtaining written consents, we accumulated samples from the patients. Parental samples were also obtained to study their carrier status.

¹Tokyo Women's Medical University Institute for Integrated Medical Sciences (TIIMS), Tokyo, Japan; ²Department of Medical Genetics, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi, Japan; ³Department of Pediatrics, Jichi Medical University, Shimotsuke, Japan; ⁴Department of Pediatrics, Osaka City University School of Medicine, Osaka, Japan and ⁵Department of Pediatrics, Juntendo University School of Medicine, Tokyo, Japan

Correspondence: Dr T Yamamoto, Tokyo Women's Medical University Institute for Integrated Medical Sciences (TIIMS), 8-1 Kawada-cho, Shinjuku-ward, Tokyo 162-8666, Japan.

E-mail: yamamoto.toshiyuki@twmu.ac.jp

Received 10 April 2012; revised 24 May 2012; accepted 25 May 2012

Methods

Genomic copy number was analyzed using the 244, 105 or 60K Human Genome CGH Microarray (Agilent Technologies, Santa Clara, CA, USA) as described previously.² Genomic DNAs were extracted from peripheral blood using a standard method. Genomic copy number aberrations were visualized using Agilent Genomic Workbench version 5.5 (Agilent Technologies).

Fluorescence *in situ* hybridization (FISH) was performed as previously described, when metaphase spreads were available.² Bacterial artificial clones were selected from the UCSC genome browser (<http://www.genome.ucsc.edu>). Physical positions refer to the March 2009 human reference sequence. Bacterial artificial clone DNAs were extracted by an automatic DNA extraction system GENE PREP STAR PI-80X (Kurabo, Osaka, Japan).

RESULTS

Chromosomal deletions

Chromosomal microarray testing revealed aberrations in the 1q43q44 region in six patients (Figure 1). In patient 1 and 2, interstitial deletions of 1.9 and 2.2 Mb, respectively, were identified within the 1q43q44 region. In patient 1, FISH analysis confirmed the deletion (Figure 2a). Subsequent FISH analysis revealed no abnormalities in the parents of both families, indicating *de novo* deletions in both patients. Molecular karyotyping defined the aberrations as

arr 1q44(243 809 193–245 665 521) × 1 dn for patient 1 and arr 1q43q44(243 303 991–245 506 920) × 1 dn for patient 2.

In patient 3, terminal deletions of 1q43 were identified and confirmed by FISH analyses (Figure 2b). As FISH analyses for both parents showed no abnormalities, this deletion occurred as *de novo*. Molecular karyotyping of patient 3 was indicated as arr 1q43q44(242 442 098–249 250 621) × 1 dn.

In patient 4, a loss of genomic copy number at 1q43q44 and an additional gain at 5p15.33 were identified (Supplementary Figure 1). Subsequent FISH analysis confirmed an unbalanced translocation between 1q43 and 5p in patient 4 (Figures 2c–e), and no translocation was found in either parents. Consequently, the patient's unbalance translocation was determined to be *de novo* in origin. Her karyotype was 46,XX,der(1)t(1;5)(q43;p15.33).arr 1q43q44(242 223 230–249 212 668) × 1, 5p15.33(57 640–1 705 515) × 3 dn. The duplicated region of 5p was only 1.7 Mb of the terminal region.

In patient 5, terminal deletions of 1q43 were identified with a breakpoint in the *v-akt murine thymoma viral oncogene homolog 3* gene (*AKT3*). The molecular karyotype was arr 1q44(243 880 099–249 212 668) × 1. The largest deletion was identified in patient 6 with arr 1q43q44(238 888 870–249 212 668) × 1.




Figure 1 Results of chromosomal microarray testing presented by Gene View of Agilent Genomic Workbench (Agilent Technologies). Vertical axis and horizontal axis represent \log_2 signal ratio and genomic position, respectively. Aberrant regions are shown by blue rectangles. Dots indicate the genomic positions and the \log_2 ratio of each probe.




Figure 2 Results of FISH analyses. (a) Loss of the green signal labeling RP11-7L23 (arrow) indicates deletion of 1q44 in patient 1. (b) Loss of the green signal labeling RP11-88N11 (arrow) indicates deletion of 1q44 in patient 3. (c–e) Confirmation of the unbalanced translocation between chromosome 1 and 5 in patient 4. Loss of the green signal labeling RP11-143E8 (arrow) indicates deletion of 1q44 (c). An additional signal labeling RP11-94J21 of 5p15.33 is present on the other chromosome (d, red signal, arrow), indicating a translocation onto chromosome 1 (e, green signal, arrow).

The result of FISH analysis were summarized in Supplementary Table 1.

CLINICAL REPORT

Patient 1

A 9-year-old boy was born by vacuum extraction. His birth weight was 2820 g (within 25th centile), length was 45 cm (= 3rd centile) and occipitofrontal circumference (OFC) was 32.5 cm (10–25th centile). After birth, he displayed feeding problem. His development was mildly delayed with head control attained at 8 months, sitting without support at 15 months, crawling at 24 months and walking alone without support at 44 months. At the age of 11 months, he experienced recurrent febrile seizures. At 18 months of age, he suffered non-febrile seizures. The brain magnetic resonance imaging (MRI) at 4 years of age revealed loss of volume in the frontal lobe, mild abnormal gyral patterns in the frontal lobe and lateral lobe, and ACC (Figures 3a–c). Conventional chromosomal analysis revealed a normal male karyotype.

At present, his height is 119.5 cm (<3rd centile) and weight is 23.6 kg (10th centile). He exhibits microcephaly with OFC of 47.5 cm (<3rd centile). He displays distinctive facial features including a flat occipit, coarse face, high nasal bridge, low-set ears and prominent jaw (Figure 4a). He has short tapering fingers and single palmer creases.

Patient 2

A 3-year and 1-month-old girl is a second child of healthy non-consanguineous parents with an unremarkable family history. She was born at 36th week of gestation after an uneventful

pregnancy. She displayed prenatal growth retardation with her weight of 2348 g (<3rd centile), length of 44.4 cm (<3rd centile) and OFC of 31 cm (<3rd centile). At the age of 6 months, developmental delay and microcephaly were noted. She could balance her head at 6 months, sit at 10 months, roll over at 13 months and crawl at 20 months. At the age of 11 months, she suffered febrile convulsion, followed by 11 recurrent attacks of complex febrile seizures. The findings of her electroencephalogram were unremarkable.

At the age of 2 years and 11 months, she had a short stature (height 79 cm, <3rd centile; weight 10 kg, <3rd centile) and microcephaly (OFC 42.5 cm, <3rd centile). Facial dysmorphism included epicanthal folds, a broad nasal root and down-turned corner of mouth (Figure 4b). Neurological examination revealed generalized hypotonia. At this time, she showed moderate psychomotor developmental delay with motor development of 10 months and language development of 8 months. Ultrasonography of the kidneys and liver, echocardiography, ophthalmologic and audiological examinations revealed no abnormalities. Conventional chromosome analysis revealed a normal female karyotype.

At present, the patient cannot stand without support. She can speak only babbled words. The brain MRI revealed ACC and loss of the volume of the frontal lobe (Figures 3d–f).

Patient 3

A 1-year and 6-month-old girl was born at the gestational age of 38 weeks by vaginal delivery. Although her pregnancy was unremarkable, she showed prenatal growth retardation with her birth weight of 2040 g (<3rd centile) and OFC of 30 cm (<3rd centile). Her APGAR score was 9/9. One hour after birth, she suffered a convulsion




Figure 3 The brain MRI findings of patient 1 examined at 4 years (a–c), patient 2 examined at 3 years (d–f), patient 3 examined at 12 months (g–i), patient 4 examined at 15 months (j–l), patient 5 examined at 5 months (m–o) and patient 6 examined at 3 years (p–r). T1-weighted sagittal views (a, d, g, j, m, p), T1-weighted axial views (b, e, h, k, n, q) and T2-weighted axial views (c, f, i, l, o, r). ACC are noted in all patients. Patient 5 (m), in particular, exhibits complete agenesis of the corpus callosum. Reduced volume of the frontal lobe is seen in all patients. Prominently delayed myelination is noted in patient 3 and 4 (i and l).

triggered by hypoglycemia. Ultrasonography showed enlarged bilateral cerebral ventricles and intraventricular hemorrhage. Echocardiography showed no abnormalities. Ophthalmologic examination displayed exotropia and atrophy of the right retina and optic papilla. Auditory brain-stem response (ABR) showed normal results. Owing to her feeding difficulty, she required tube feeding. At the age of 5 months, she experienced a status convulsive epilepticus, and recurrent spike and waves were noted on EEG at that time. She was treated with several antiepileptic drugs. The brain MRI examined at 1 year of age showed ACC and reduced volume of the brain (Figures 3g–i). Low

intensity of the white matter was only noted on the posterior limb of internal capsule, indicating delayed myelination (Figure 3i).

At 1 year and 6 months, the patient could not control her head by herself. She did not demonstrate eye contact, and her feeding difficulties persisted. Distinct facial features included sparse hair, microcephaly, a flat occipit, a coarse face, a high nasal bridge, low-set ears, micrognathia, inversion of eyelids, esotropia and atopic skin. Immediately after this examination, acute respiratory infectious disease caused hypoxic brain damages, which was confirmed by brain computed tomography that revealed the presence of multi-cystic lesions (data not shown). After this event, she shows spastic quadriplegia.




Figure 4 Facial features of patient 1 (a) and patient 2 (b). Arched eyebrows and small mouth are noted in both patients.

Patient 4

A 3-year and 3-month-old girl was born by induced delivery at 37th week as a first child of healthy, non-consanguineous parents. She showed prenatal growth retardation with her birth weight of 2386 g (<3rd centile), length of 44 cm (<3rd centile) and OFC 31 cm (<3rd centile). Atrial septal defect was revealed by ultrasonography. She displayed psychomotor developmental delay with holding up her head at 5 months, sitting by herself at 14 months and crawling at 20 months. From the age of 14 months, she was prescribed with antiepileptic drugs because of status convulsive that continued for ~1 h. The brain MRI examined at an age of 15 months revealed ACC and hypoplastic brain (Figures 3j–l). Low intensity of the white matter was only noted in the posterior limb of the internal capsule, indicating delayed myelination (Figure 3l). Conventional karyotyping on metaphase spreads prepared from peripheral lymphocytes showed a normal female karyotype.




Figure 5 Deletions regions of the present patients depicted on a genome map from UCSC Genome Browser. Blue rectangles indicate the deletion region of the interstitial deletions identified on patients 1 and 2. Blue trapezoids indicate the terminal deletions identified on patients 3–6. Directions of the pointed trapezoids indicate continuous deletions to the telomeres. The region responsible for microcephaly, ACC and seizure that were proposed by Ballif *et al.*¹⁷ are shown by gray rectangles.

Table 1 Summary of the clinical features of six patients in this study

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Frequency reported by van Bon <i>et al.</i> ^{1,3}
Karyotype	del (1) (q44q44)	del (1) (q43q44)	del (1) (q43)	del (1) (q43)	del (1) (q44)	del (1) (q43)	
Type of aberrations	Interstitial deletion	Interstitial deletion	Subtelomeric deletion	Unbalanced translocation	Subtelomeric deletion	Subtelomeric deletion	
<i>Deletion region</i>							
Start ^a	243 809 193	243 303 991	242 442 098	242 223 230	243 880 099	238 888 870	
End ^a	245 665 521	245 506 920	249 250 621	249 212 668	249 212 668	249 212 668	
Size (Mb)	1.9	2.2	6.8	7.0	5.3	10.3	
Gender	M	F	F	F	F	F	
Age	9 years	3 years and 1 month	1 year and 6 months	3 years and 3 months	6 years	10 years	
Birth weight (g)	2820	2348	2040	2386	1870	NA	
<i>Controversial points for 1q43 deletions</i>							
Microcephaly	+	+	+	+	+	+	9/11
Abnormalities of the corpus callosum	-	+	+	+	+	+	9/10
Seizures	+	+	+	+	+	+	9/11
Delayed myelination	-	-	+	+	NA	NA	
Severe volume loss of the brain	-	-	+	+	+	+	
<i>General findings</i>							
Developmental delay/mental retardation	+	+	+	+	+	+	11/11
Growth retardation	+	+	NA	+	+	+	7/11
Low birth weight	-	+	+	+	+	NA	5/11
Hypotonia	NA	+	+	NA	+	+	11/11
Feeding problem	+	-	+	-	+	NA	
<i>Facial findings</i>							
Round face	-	+	+	+	NA	NA	7/11
Arched eyebrows	+	+	+	+	NA	NA	
High nasal bridge	+	-	+	-	NA	NA	
Upward-slanting palpebral fissures	+	+	+	+	NA	NA	3/11
Epicanthic folds	+	+	+	+	NA	NA	4/11
Strabismus	+	-	+	-	NA	NA	2/11
Micro/retrognathia	-	-	+	+	NA	NA	0/11
Prominent jaw	+	-	-	-	NA	NA	
Low-set ears	+	+	+	+	NA	NA	
Down-turned corner of mouth	+	+	+	+	NA	NA	
<i>Other features</i>							
Sparse hair	-	-	+	-	NA	NA	
Flat occipit	+	-	+	-	NA	NA	
Tapering fingers	+	-	-	-	NA	NA	
Single palmer creases	+	-	-	-	NA	NA	
<i>Complications of other organs</i>							
Cardiac anomaly	-	-	-	ASD	-	AR	3/11
Kidney/urine pathway anomaly	-	-	-	-	Hydronephrosis	-	2/11

Abbreviations: AR, aortic regurgitation; ASD, atrial septal defect; F, female; M, male; NA, not available.
^aGenomic positions refer to build 19.

At present, the patient exhibits severe developmental delay as she cannot stand without support and her language usage is limited to babbled words. Her mental and psychomotor developmental index of

the Bayley Scales of Infant Development (II) indicate 6 and 8 months, respectively. She demonstrates growth deficiency and microcephaly with her weight of 12.8 kg (25–50th centile), height of 87.7 cm

(10th centile) and OFC of 44 cm (<3rd centile). Dysmorphic features include hypertelorism, low-set ears and micrognathia.

Patient 5

A 6-year-old girl was born at 38 weeks of gestation, with birth weight of 1870 g (<3rd centile), length of 42 cm (<3rd centile) and OFC of 28 cm (<3rd centile), indicating intrauterine growth restriction. Since early infancy, she exhibited severe hypotonia, and her psychomotor development was severely delayed. She experienced refractory seizures after 1 year of age. Although hydronephrosis was noted by abdominal ultrasonography, there was no abnormal renal function. The brain MRI examined at an age of 4 months revealed a hypoplastic brain associated with complete agenesis of the corpus callosum (Figures 3m–o). As a result of recurrent aspiration pneumonia, laryngotracheal separation surgery was performed. At present, her height is 99 cm (<3rd centile), weight is 15.3 kg (<3rd centile) and OFC of 42 cm (<3rd centile), indicating severe growth deficiency and microcephaly. She can stand by support, but no meaningful words.

Patient 6

A 10-year-old girl was born at 40 weeks and 3 days of gestation. At the age of 3 years, she was referred to our institution because of intractable epilepsy. At that time, neurological examination revealed generalized hypotonia. EEG showed frequent spikes on the left hemisphere. The brain MRI indicated a hypoplastic brain associated with ACC and delayed myelination (Figures 3p–r). Echocardiography revealed mild aortic regurgitation. At present, her height is 115 cm (<3rd centile), weight is 16.3 kg (<3rd centile) and OFC of 48 cm (<3rd centile), indicating growth delay and microcephaly. She shows severe psychomotor developmental delay with sitting by support and no meaningful word.

DISCUSSION

The characteristics of 1q44 deletions have been recognized as growth deficiency, psychomotor developmental delay, epilepsy, microcephaly, brain malformations including ACC, and distinct facial features.^{4,6,7,9,11,18} After chromosomal microarray testing has been available for the identification of submicroscopic chromosomal aberrations, many patients with submicroscopic deletions of 1q44 have been identified.^{8,10,12,14,15} Now, precise genotype–phenotype correlation has been evaluated through the accumulation of patients with variable deletion sizes, and a minimal essential region has been proposed for expressing the main characteristics of 1q44 deletion syndrome.^{7,8,14–16} Ballif *et al.*¹⁷ evaluated 22 patients with small interstitial deletions of 1q44 and demonstrated critical regions for microcephaly, ACC and seizures. Consequently, *AKT3* was reported to be the gene responsible for microcephaly; zinc finger protein 238 gene (*ZNF238*) for ACC; and heterogeneous nuclear ribonucleoprotein U gene (*HNRNPU*) for seizures¹⁷ (Figure 5).

In this study, we identified six patients with the deletions including 1q44. Clinical and genetic findings were summarized in Table 1 and Figure 5, respectively. The presenting patient 1 and 2 showed typical interstitial deletions of 1q44, in which *AKT3* and *ZNF238* are included, and manifested the typical features of mental retardation, microcephaly, ACC and seizures. This evidence supports the findings reported by Ballif *et al.* that the essential features of 1q44 deletion syndrome are derived from deletions of the minimal region including *AKT3* and *ZNF238*.¹⁷ In comparison with these two patients, the other four patients displayed terminal deletion of 1q44 that include the minimal region including *AKT3* and *ZNF238*.

Although the chromosomal breakpoint of patient 5 was just on *AKT3*, phenotypic feature of this patient are extremely severe as compared with those of patient 1 and 2 who had interstitial deletion of 1q44. Although Roos *et al.*¹⁸ reported that 1.6 Mb terminal region does not have clinical relevance, because it appears to primarily contain many of the olfactory receptors genes, many genes of unknown functions are included in this 2.6 Mb region (chr1:245 000 000–247 600 000). Thus, this additionally deleted region in patient 5 may also have been responsible for his severe neurological manifestations.

Patient 4 had an additional chromosomal aberration, with a partial trisomy of 5p derived from an unbalanced translocation. However, the phenotypic severity of patient 4 was not significantly different from that of the other patients with 1q43 deletions. Thus, the partial trisomy of 5p identified in patient 4 did not demonstrate an important contribution to the patient's manifestations. Patient 3 showed extremely severe developmental delay, which may have been modified by the hypoglycemia and subsequent intraventricular hemorrhage suffered during the early infantile period.

The deletion regions of the remaining three patients (patient 3, 4 and 6) expanded toward the centromere beyond the critical region for 1q44 deletion syndrome, and several more genes are included in the deletion region in these three patients. Severe volume loss of the brain was revealed in the brain MRI of these three patients, similar to patient 5, and delayed myelination was also seen on the brain MRI of patient 3 and 4 (Figures 3i, l). Although patient 5 exhibited high T2 signal intensities in the white matter, this image was obtained when he was 4 months of age, and we cannot ascertain if this finding indicated delayed myelination. Similarly, because the brain MRI of patient 1, 2 and 6 were obtained after 3 years of age, we cannot determine whether these three patients experienced delayed myelinations in their early infancy. However, delayed myelination, as a finding associated with 1q44 deletion, has not yet been reported in the literature.¹⁷ It may therefore be that the characteristic findings of the patients with expanded deletion beyond the 1q43 region may have clinical implications for delayed myelination. Although many UCSC genes are present in these additional regions, some of these genes may have clinical relevance for delayed myelination observed in patient 3 and 4. The centrosomal protein 170 kDa gene (*CEP170*) is a potential candidate because of its high expression level in the fetal brain.

In this genotype–phenotype correlation study for patients with 1q44 deletions, we revealed that telemetric region beyond the physical position of chr1:245 000 000 may be responsible for severe volume loss of the brain, and the proximal region beyond *AKT3* may be responsible for delayed myelination. The neighboring genes surrounding 1q43q44 may have some modifier effects to the severe brain impairments associated with delayed myelination. To identify them, much more information regarding genotype–phenotype correlations will need to be accumulated for patients with terminal deletion of 1q.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

We thank the patients and their parents for their gracious participation and support. This work was supported by Grant-in-Aid for Research Activity Start-up for KS and Grant-in-Aid for Scientific Research (C) for TY from the Japan Ministry of Education, Science, Sports and Culture.

- 1 Knight, S. J., Regan, R., Nicod, A., Horsley, S. W., Kearney, L., Hornfray, T. *et al*. Subtle chromosomal rearrangements in children with unexplained mental retardation. *Lancet* **354**, 1676–1681 (1999).
- 2 Shimojima, K., Sugiura, C., Takahashi, H., Ikegami, M., Takahashi, Y., Ohno, K. *et al*. Genomic copy number variations at 17p13.3 and epileptogenesis. *Epilepsy Res.* **89**, 303–309 (2010).
- 3 Cardoso, C., Leventer, R. J., Ward, H. L., Toyo-Oka, K., Chung, J., Gross, A. *et al*. Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other phenotypes secondary to deletions of 17p13.3. *Am. J. Hum. Genet.* **72**, 918–930 (2003).
- 4 Gentile, M., Di Carlo, A., Volpe, P., Pansini, A., Nanna, P., Valenzano, M. C. *et al*. FISH and cytogenetic characterization of a terminal chromosome 1q deletion: clinical case report and phenotypic implications. *Am. J. Med. Genet. A* **117A**, 251–254 (2003).
- 5 Puthuran, M. J., Rowland-Hill, C. A., Simpson, J., Pairaudeau, P. W., Mabbott, J. L., Morris, S. M. *et al*. Chromosome 1q42 deletion and agenesis of the corpus callosum. *Am. J. Med. Genet. A* **138**, 68–69 (2005).
- 6 van Bever, Y., Rooms, L., Laridon, A., Reyniers, E., van Luijk, R., Scheers, S. *et al*. Clinical report of a pure subtelomeric 1qter deletion in a boy with mental retardation and multiple anomalies adds further evidence for a specific phenotype. *Am. J. Med. Genet. A* **135**, 91–95 (2005).
- 7 Boland, E., Clayton-Smith, J., Woo, V. G., McKee, S., Manson, F. D., Medne, L. *et al*. Mapping of deletion and translocation breakpoints in 1q44 implicates the serine/threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum. *Am. J. Hum. Genet.* **81**, 292–303 (2007).
- 8 Hill, A. D., Chang, B. S., Hill, R. S., Garraway, L. A., Bodell, A., Sellers, W. R. *et al*. A 2-Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndrome. *Am. J. Med. Genet. A* **143A**, 1692–1698 (2007).
- 9 Merritt, II J. L., Zou, Y., Jalal, S. M. & Michels, V. V. Delineation of the cryptic 1qter deletion phenotype. *Am. J. Med. Genet. A* **143**, 599–603 (2007).
- 10 Andrieux, J., Cuvellier, J. C., Duban-Bedu, B., Joriot-Chekaf, S., Dieux-Coeslier, A., Manouvrier-Hanu, S. *et al*. A 6.9 Mb 1qter deletion/4.4 Mb 18pter duplication in a boy with extreme microcephaly with simplified gyral pattern, vermis hypoplasia and corpus callosum agenesis. *Eur. J. Med. Genet.* **51**, 87–91 (2008).
- 11 Hiraki, Y., Okamoto, N., Ida, T., Nakata, Y., Kamada, M., Kanemura, Y. *et al*. Two new cases of pure 1q terminal deletion presenting with brain malformations. *Am. J. Med. Genet. A* **146A**, 1241–1247 (2008).
- 12 Poot, M., Kroes, H. Y. & Hochstenbach, R. AKT3 as a candidate gene for corpus callosum anomalies in patients with 1q44 deletions. *Eur. J. Med. Genet.* **51**, 689–690 (2008).
- 13 van Bon, B. W., Koolen, D. A., Borgatti, R., Magee, A., Garcia-Minaur, S., Rooms, L. *et al*. Clinical and molecular characteristics of 1qter microdeletion syndrome: delineating a critical region for corpus callosum agenesis/hypogenesis. *J. Med. Genet.* **45**, 346–354 (2008).
- 14 Orellana, C., Rosello, M., Monfort, S., Oltra, S., Quiroga, R., Ferrer, I. *et al*. Corpus callosum abnormalities and the controversy about the candidate genes located in 1q44. *Cytogenet. Genome Res.* **127**, 5–8 (2009).
- 15 Caliebe, A., Kroes, H. Y., van der Smagt, J. J., Martin-Subero, J. I., Tonnie, H., van't Slot, R. *et al*. Four patients with speech delay, seizures and variable corpus callosum thickness sharing a 0.440 Mb deletion in region 1q44 containing the HNRPU gene. *Eur. J. Med. Genet.* **53**, 179–185 (2010).
- 16 Nagamani, S. C., Erez, A., Bay, C., Pettigrew, A., Lalani, S. R., Herman, K. *et al*. Delineation of a deletion region critical for corpus callosal abnormalities in chromosome 1q43-q44. *Eur. J. Hum. Genet.* **20**, 176–179 (2012).
- 17 Ballif, B. C., Rosenfeld, J. A., Traylor, R., Theisen, A., Bader, P. I., Ladda, R. L. *et al*. High-resolution array CGH defines critical regions and candidate genes for microcephaly, abnormalities of the corpus callosum, and seizure phenotypes in patients with microdeletions of 1q43q44. *Hum. Genet.* **131**, 145–156 (2012).
- 18 Roos, A., Eggermann, T., Zerres, K. & Schuler, H. M. Polymorphic subtelomeric deletion 1q demonstrates the need to reevaluate subtelomere screening methods: determination of the boundary between pathogenic deletion and benign variant for subtelomere 1q. *Am. J. Med. Genet. A* **146A**, 795–798 (2008).

Supplementary Information accompanies the paper on Journal of Human Genetics website (<http://www.nature.com/jhg>)